Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 3/20 | 0.45 |
| ▸ | ACHE | P22303 | 3/20 | 0.45 |
| ▸ | APP | P05067 | 2/20 | 0.45 |
| ▸ | CD38 | P28907 | 1/20 | 0.43 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.42 |
| ▸ | PDE1A | P54750 | 4/20 | 0.42 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.42 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PRKACA | P17612 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30093063 | 0.94 | CCR4 (0.44) | CCR4BCHEACHEAPPCD38 | |
| SCHEMBL21542069 | 0.89 | CD38 (0.45) | CCR4BCHEACHEAPPCD38 | |
| SCHEMBL21542064 | 0.88 | BCHE (0.61) | CCR4BCHEACHEAPPCD38 | |
| SCHEMBL30092920 | 0.88 | BCHE (0.61) | CCR4BCHEACHEAPPCD38 | |
| SCHEMBL21542045 | 0.88 | PIP4K2C (0.51) | CCR4BCHEACHEAPPPIP4K2C | |
| SCHEMBL21541997 | 0.86 | CD38 (0.43) | CCR4CD38PIP4K2CPDE1APDE1B | |
| SCHEMBL21542006 | 0.83 | PIP4K2C (0.46) | CCR4BCHEACHEAPPPIP4K2C | |
| SCHEMBL20399166 | 0.83 | CD38 (0.48) | CCR4CD38PIP4K2CPDE1APDE1B | |
| SCHEMBL21542070 | 0.83 | APP (0.53) | CCR4BCHEACHEAPPPIP4K2C | |
| SCHEMBL20400138 | 0.83 | BCHE (0.45) | BCHEACHEAPPCD38PIP4K2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545675-B2 | Anti-wolbachia pyrido[2,3-d]pyrimidine compounds | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2026-02-10 | — | — | US | disclosed |
| US-20240108629-A1 | AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL | LIVERPOOL SCHOOL TROPICAL MEDICINE (GB) | 2024-04-04 | — | — | US | disclosed |
| EP-4277631-A1 | AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL | Liverpool School of Tropical Medicine (GB) | 2023-11-22 | — | — | EP | disclosed |
| US-20230348460-A1 | ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS | THE UNIVERSITY OF LIVERPOOL (GB) | 2023-11-02 | — | — | US | disclosed |
| US-20230348460-A1 | ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS | THE UNIVERSITY OF LIVERPOOL (GB) | 2023-11-02 | — | — | US | disclosed |
| US-11518760-B2 | Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2022-12-06 | — | — | US | disclosed |
| WO-2022152918-A1 | AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2022-07-21 | — | — | WO | disclosed |
| US-20190345157-A1 | COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-11-14 | — | — | US | disclosed |
| US-20190345157-A1 | COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545675-B2 | Anti-wolbachia pyrido[2,3-d]pyrimidine compounds | CBR1, CBR3, COX6C | CCR4 101/4885BCHE 2784/4885ACHE 2483/4885 |
| US-20230348460-A1 | ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS | PWWP2B, WARS1, PNPO | CCR4 3571/4885BCHE 3860/4885ACHE 1710/4885 |
| US-20190345157-A1 | COMPOUNDS | ABCB11, LTC4S, AQP1 | CCR4 752/4885BCHE 632/4885ACHE 297/4885 |
| US-11518760-B2 | Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds | P2RX5, PNPO, P2RX3 | CCR4 3139/4885BCHE 3579/4885ACHE 1142/4885 |
| US-20240108629-A1 | AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL | AQP3, AQP1, AQP4 | CCR4 2777/4885BCHE 746/4885ACHE 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.